Histrelin

Histrelin
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Histrelin is a endocrine-metabolic agent and gonadotropin releasing hormone agonist that is FDA approved for the treatment of children with central precocious puberty ([CPP]]). Common adverse reactions include implant site reactions, gynecomastia, hot sweats, amenorrhea, erectile dysfunction and fatigue.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Histrelin FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Histrelin in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Histrelin in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Histrelin FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Histrelin in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Histrelin in pediatric patients.

Contraindications

• SUPPRELIN LA is contraindicated in patients who are hypersensitive to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs.
• SUPPRELIN LA is contraindicated in females who are or may become pregnant while receiving the drug. SUPPRELIN LA may cause fetal harm when administered to pregnant patients. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. The possibility exists that spontaneous abortion may occur.

Warnings

Initial Agonistic Action

• SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms during this period. However, within 4 weeks of histrelin therapy, suppression of gonadal steroids occurs and manifestations of puberty decrease.

Implant Insertion/Removal Procedure

• Implant insertion is a surgical procedure and it is important that the insertion instructions are followed to avoid potential complications. The insertion and removal of the implant should be done aseptically. Proper surgical technique is critical in minimizing adverse events related to the insertion and the removal of the histrelin implant. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (note: the histrelin implant is not radiopaque). In some cases the implant broke during removal and multiple pieces were recovered. Confirm that the entire implant has been removed. If the implant was not retrieved completely, the remaining pieces should be removed following the instructions in the Suggested Removal Procedure section. Rare events of spontaneous extrusion of the implant have been observed in clinical trials. During SUPPRELIN LA treatment, patients should be evaluated for evidence of clinical and biochemical suppression of CPP manifestations (see SECTION 5.3, Monitoring and Laboratory tests). Detailed instructions on the insertion and removal procedures of the implant are provided above.

Monitoring and Laboratory Tests

• LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months thereafter. Additionally, height (for calculation of height velocity) and bone age should be assessed every 6-12 months.

Adverse Reactions

Clinical Trials Experience

The most common adverse reactions with SUPPRELIN LA involved the implant site. Local reactions after implant insertion include bruising, pain, soreness, erythema and swelling. During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the natural stimulatory effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed

Adverse Reactions in Clinical Trials

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of SUPPRELIN LA in children with CPP was evaluated in two single-arm clinical trials conducted in a total of 47 patients (44 females and 3 males) over a period of time ranging from 9 to 18 months. The most commonly reported adverse reaction was implant site reaction, which was reported by 24 of 47 (51.1%) patients. Implant site reaction includes discomfort, bruising, soreness, pain, tingling, itching, implant area protrusion and swelling. Two subjects experienced a serious adverse reaction: 1 subject who coincidentally had Stargardt’s Disease experienced amblyopia and 1 subject had a benign pituitary tumor (pituitary adenoma). One subject discontinued the study due to an adverse reaction of infection at the implant site. There were no clinically meaningful findings in standard clinical hematology and chemistry tests and/or in vital signs. The incidence of implantation adverse events reported by more than 2 patients are summarized in Table 1.

The following adverse reactions were reported as possibly related or related in 1 patient each: wound infection, breast tenderness, dysmenorrhea, epistaxis, erythema, feeling cold, gynecomastia, headache, menorrhagia, migraine, mood swings, pituitary tumor benign, pruritus, weight increased, disease progression and influenza-like illness. The adverse reaction metrorrhagia was reported as possibly related or related in 2 patients.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of SUPPRELIN LA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General Disorders and Administration Site Conditions: implant breakage Nervous System Disorders: seizures

Drug Interactions

• Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA.

• Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin-like growth factor-1 (IGF-1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (D

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Histrelin in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Histrelin in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Histrelin during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Histrelin in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Histrelin in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Histrelin in geriatric settings.

Gender

There is no FDA guidance on the use of Histrelin with respect to specific gender populations.

Race

There is no FDA guidance on the use of Histrelin with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Histrelin in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Histrelin in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Histrelin in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Histrelin in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Histrelin Administration in the drug label.

Monitoring

There is limited information regarding Histrelin Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Histrelin and IV administrations.

Overdosage

There is limited information regarding Histrelin overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Histrelin Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Histrelin Mechanism of Action in the drug label.

Structure

There is limited information regarding Histrelin Structure in the drug label.

Pharmacodynamics

There is limited information regarding Histrelin Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Histrelin Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Histrelin Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Histrelin Clinical Studies in the drug label.

How Supplied

There is limited information regarding Histrelin How Supplied in the drug label.

Storage

There is limited information regarding Histrelin Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Histrelin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Histrelin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Histrelin Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Histrelin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Histrelin Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Histrelin Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Histrelin

Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Subcutaneous implant
ATC code	H01CA03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	92%
Protein binding	70%
Metabolism	Hepatic
Elimination half-life	4 hours
Excretion	Undetermined
Identifiers
CAS Number	76712-82-8
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C66H86N18O12
Molar mass	1323.5 g/mol

WikiDoc Resources for Histrelin
Articles
Most recent articles on Histrelin Most cited articles on Histrelin Review articles on Histrelin Articles on Histrelin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Histrelin Images of Histrelin Photos of Histrelin Podcasts & MP3s on Histrelin Videos on Histrelin
Evidence Based Medicine
Cochrane Collaboration on Histrelin Bandolier on Histrelin TRIP on Histrelin
Clinical Trials
Ongoing Trials on Histrelin at Clinical Trials.gov Trial results on Histrelin Clinical Trials on Histrelin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Histrelin NICE Guidance on Histrelin NHS PRODIGY Guidance FDA on Histrelin CDC on Histrelin
Books
Books on Histrelin
News
Histrelin in the news Be alerted to news on Histrelin News trends on Histrelin
Commentary
Blogs on Histrelin
Definitions
Definitions of Histrelin
Patient Resources / Community
Patient resources on Histrelin Discussion groups on Histrelin Patient Handouts on Histrelin Directions to Hospitals Treating Histrelin Risk calculators and risk factors for Histrelin
Healthcare Provider Resources
Symptoms of Histrelin Causes & Risk Factors for Histrelin Diagnostic studies for Histrelin Treatment of Histrelin
Continuing Medical Education (CME)
CME Programs on Histrelin
International
Histrelin en Espanol Histrelin en Francais
Business
Histrelin in the Marketplace Patents on Histrelin
Experimental / Informatics
List of terms related to Histrelin

Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

Histrelin is marketed by Indevus Pharmaceuticals under the brand names Vantas and Supprelin LA.

Pharmacology

In a process known as downregulation, daily stimulation of pituitary gonadotropes causes them to become desensitized to the effects of histrelin. As a consequence, levels of LH and FSH fall after a short period of time. From that point forward, as long as histrelin is administered, the levels of LH and FSH in the blood remain low.

This prolonged lowering of LH and FSH levels is the rationale for therapy using GnRH agonists. Since LH and FSH stimulate the gonads to produce estrogens and androgens in females and males respectively, histrelin can effectively be used to decrease the sex steroids in the blood of patients.

Indications

Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin has been proven to be highly effective in treating central precocious puberty in children.

It is available as a daily intramuscular injection. Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer. A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration.

References

Template:WikiDoc Sources